250 related articles for article (PubMed ID: 12576925)
21. Alterations in tumor necrosis factor signaling pathways are associated with cytotoxicity and resistance to taxanes: a study in isogenic resistant tumor cells.
Sprowl JA; Reed K; Armstrong SR; Lanner C; Guo B; Kalatskaya I; Stein L; Hembruff SL; Tam A; Parissenti AM
Breast Cancer Res; 2012 Jan; 14(1):R2. PubMed ID: 22225778
[TBL] [Abstract][Full Text] [Related]
22. Gef gene therapy enhances the therapeutic efficacy of doxorubicin to combat growth of MCF-7 breast cancer cells.
Prados J; Melguizo C; Rama AR; Ortiz R; Segura A; Boulaiz H; Vélez C; Caba O; Ramos JL; Aránega A
Cancer Chemother Pharmacol; 2010 May; 66(1):69-78. PubMed ID: 19771430
[TBL] [Abstract][Full Text] [Related]
23. Risks and benefits of taxanes in breast and ovarian cancer.
Michaud LB; Valero V; Hortobagyi G
Drug Saf; 2000 Nov; 23(5):401-28. PubMed ID: 11085347
[TBL] [Abstract][Full Text] [Related]
24. Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs.
Tanabe K; Kim R; Inoue H; Emi M; Uchida Y; Toge T
Int J Oncol; 2003 Apr; 22(4):875-81. PubMed ID: 12632082
[TBL] [Abstract][Full Text] [Related]
25. Telomerase enzyme activity and RNA expression in adriamycin-resistant human breast carcinoma MCF-7 cells.
Ishikawa T; Kamiyama M; Hisatomi H; Ichikawa Y; Momiyama N; Hamaguchi Y; Hasegawa S; Narita T; Shimada H
Cancer Lett; 1999 Jul; 141(1-2):187-94. PubMed ID: 10454261
[TBL] [Abstract][Full Text] [Related]
26. Survival of docetaxel-resistant prostate cancer cells in vitro depends on phenotype alterations and continuity of drug exposure.
Makarovskiy AN; Siryaporn E; Hixson DC; Akerley W
Cell Mol Life Sci; 2002 Jul; 59(7):1198-211. PubMed ID: 12222966
[TBL] [Abstract][Full Text] [Related]
27. Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP).
Vanhoefer U; Cao S; Harstrick A; Seeber S; Rustum YM
Ann Oncol; 1997 Dec; 8(12):1221-8. PubMed ID: 9496387
[TBL] [Abstract][Full Text] [Related]
28. Docetaxel in anthracycline-resistant metastatic breast cancer.
Hui YF; Ignoffo RJ
Cancer Pract; 1997; 5(2):124-7. PubMed ID: 9110651
[TBL] [Abstract][Full Text] [Related]
29. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel.
Zhang L; Lau YK; Xia W; Hortobagyi GN; Hung MC
Clin Cancer Res; 1999 Feb; 5(2):343-53. PubMed ID: 10037184
[TBL] [Abstract][Full Text] [Related]
30. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
Menendez JA; Vellon L; Lupu R
Int J Mol Med; 2006 Dec; 18(6):1081-7. PubMed ID: 17089011
[TBL] [Abstract][Full Text] [Related]
31. Anti-proliferative activity of a new class of taxanes (14beta-hydroxy-10-deacetylbaccatin III derivatives) on multidrug-resistance-positive human cancer cells.
Distefano M; Scambia G; Ferlini C; Gaggini C; De Vincenzo R; Riva A; Bombardelli E; Ojima I; Fattorossi A; Panici PB; Mancuso S
Int J Cancer; 1997 Sep; 72(5):844-50. PubMed ID: 9311603
[TBL] [Abstract][Full Text] [Related]
32. Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro.
Hill BT; Whelan RD; Shellard SA; McClean S; Hosking LK
Invest New Drugs; 1994; 12(3):169-82. PubMed ID: 7896535
[TBL] [Abstract][Full Text] [Related]
33. Cytotoxic effects toward human hematopoietic progenitor cells and tumor cell lines of paclitaxel, docetaxel, and newly developed analogues IDN5109, IDN5111, and IDN5127.
Ferlini C; Distefano M; Pierelli L; Bonanno G; Riva A; Bombardelli E; Ojima I; Mancuso S; Scambia G
Oncol Res; 1999; 11(10):471-8. PubMed ID: 10850888
[TBL] [Abstract][Full Text] [Related]
34. Acquired antiestrogen resistance in MCF-7 human breast cancer sublines is not accomplished by altered expression of receptors in the ErbB-family.
Larsen SS; Egeblad M; Jäättelä M; Lykkesfeldt AE
Breast Cancer Res Treat; 1999 Nov; 58(1):41-56. PubMed ID: 10634517
[TBL] [Abstract][Full Text] [Related]
35. Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer.
Tan MH; De S; Bebek G; Orloff MS; Wesolowski R; Downs-Kelly E; Budd GT; Stark GR; Eng C
Breast Cancer Res Treat; 2012 Feb; 131(3):849-58. PubMed ID: 21479552
[TBL] [Abstract][Full Text] [Related]
36. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells.
Pegram MD; Finn RS; Arzoo K; Beryt M; Pietras RJ; Slamon DJ
Oncogene; 1997 Jul; 15(5):537-47. PubMed ID: 9247307
[TBL] [Abstract][Full Text] [Related]
37. Docetaxel in breast cancer and a rationale for combination therapy.
Hortobágyi G
Oncology (Williston Park); 1997 Jun; 11(6 Suppl 6):11-5. PubMed ID: 9213321
[TBL] [Abstract][Full Text] [Related]
38. Tumor-targeting, systemically delivered antisense HER-2 chemosensitizes human breast cancer xenografts irrespective of HER-2 levels.
Rait AS; Pirollo KF; Xiang L; Ulick D; Chang EH
Mol Med; 2002 Aug; 8(8):475-86. PubMed ID: 12435858
[TBL] [Abstract][Full Text] [Related]
39. Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind.
Verweij J; Clavel M; Chevalier B
Ann Oncol; 1994 Jul; 5(6):495-505. PubMed ID: 7918121
[TBL] [Abstract][Full Text] [Related]
40. Establishment of paclitaxel-resistant breast cancer cell line and nude mice models, and underlying multidrug resistance mechanisms in vitro and in vivo.
Chen SY; Hu SS; Dong Q; Cai JX; Zhang WP; Sun JY; Wang TT; Xie J; He HR; Xing JF; Lu J; Dong YL
Asian Pac J Cancer Prev; 2013; 14(10):6135-40. PubMed ID: 24289639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
